{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:11:58Z","timestamp":1788448318575,"version":"build-2803163510"},"reference-count":39,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCR-20-20749"],"award-info":[{"award-number":["NCR-20-20749"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,11,14]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) comprises the triad of chronic rhinosinusitis with nasal polyps, asthma and intolerance to NSAIDs. Dupilumab treatment, targeting the interleukin-4 (IL-4) receptor \u03b1, significantly reduces polyp burden as well as asthma symptoms. Here we aimed to investigate the effect of dupilumab on aspirin intolerance, burden of disease and nasal cytokine profiles in patients with N-ERD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this open-label trial, adult patients with confirmed N-ERD were treated with dupilumab for 6\u2005months. Clinical parameters (\n                      <jats:italic>e.g.<\/jats:italic>\n                      total polyp scores, quality of life questionnaires, smell test, spirometry), oral aspirin provocation testing and blood, nasal and urine sampling were monitored at regular intervals for up to 6\u2005months after starting dupilumab therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 31 patients included in the study, 30 completed both aspirin provocation tests. After 6\u2005months of treatment with dupilumab, 23% of patients (n=7 of 30) developed complete aspirin tolerance and an additional 33% of patients (n=10 of 30) tolerated higher doses. Polyp burden was significantly reduced (total polyp score: \u22122.68\u00b11.84, p&lt;0.001), while pulmonary symptoms (asthma control test: +2.34\u00b13.67, p&lt;0.001) and olfactory performance improved (University of Pennsylvania Smell Identification Test: +11.16\u00b19.54, p&lt;0.001) in all patients after therapy. Patients with increased aspirin tolerance showed a significant decrease in urinary leukotriene E4 levels and their improvement in clinical parameters was associated with a reduction of eotaxin-1, C-C motif chemokine ligand 17, IL-5, IL-17A and IL-6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, 57% of N-ERD patients tolerated higher doses of aspirin under dupilumab therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01335-2022","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T08:00:14Z","timestamp":1671696014000},"page":"2201335","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":40,"title":["Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease"],"prefix":"10.1183","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-3746","authenticated-orcid":false,"given":"Sven","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Poglitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Gangl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bartosik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas James","family":"Campion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Tianxiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9660-2625","authenticated-orcid":false,"given":"Lukas David","family":"Landegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldine","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Stanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Rocha-Hasler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3392-6590","authenticated-orcid":false,"given":"Christine","family":"Bangert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Eckl-Dorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"2024102103094943000_61.3.2201335.1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaip.2014.09.009","article-title":"Aspirin or other nonsteroidal inflammatory agent exacerbated asthma","volume":"2","author":"Ledford","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103094943000_61.3.2201335.2","first-page":"45","article-title":"Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management","volume":"7","author":"Li","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"2024102103094943000_61.3.2201335.3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2019","journal-title":"Rhinology"},{"key":"2024102103094943000_61.3.2201335.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.020"},{"key":"2024102103094943000_61.3.2201335.5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103094943000_61.3.2201335.6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3390\/jcm9040925","article-title":"Associations between the quality of life and nasal polyp size in patients suffering from chronic rhinosinusitis without nasal polyps, with nasal polyps or aspirin-exacerbated respiratory disease","volume":"9","author":"Schneider","year":"2020","journal-title":"J Clin Med"},{"key":"2024102103094943000_61.3.2201335.7","doi-asserted-by":"crossref","first-page":"734733","DOI":"10.3389\/falgy.2021.734733","article-title":"Pathomechanisms of AERD \u2013 recent advances","volume":"2","author":"Lyly","year":"2021","journal-title":"Front Allergy"},{"key":"2024102103094943000_61.3.2201335.8","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103094943000_61.3.2201335.9","doi-asserted-by":"crossref","first-page":"850494","DOI":"10.3389\/fimmu.2022.850494","article-title":"Comprehensive analysis of nasal polyps reveals a more pronounced type 2 transcriptomic profile of epithelial cells and mast cells in aspirin-exacerbated respiratory disease","volume":"13","author":"Bangert","year":"2022","journal-title":"Front Immunol"},{"key":"2024102103094943000_61.3.2201335.10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103094943000_61.3.2201335.11","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103094943000_61.3.2201335.12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaip.2021.09.050","article-title":"Omalizumab-induced aspirin tolerance in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease patients is independent of atopic sensitization","volume":"10","author":"Quint","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103094943000_61.3.2201335.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32218-4"},{"key":"2024102103094943000_61.3.2201335.14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy"},{"key":"2024102103094943000_61.3.2201335.15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"2024102103094943000_61.3.2201335.16","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.600"},{"key":"2024102103094943000_61.3.2201335.17","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2022. Available from: http:\/\/ginasthma.org\/"},{"key":"2024102103094943000_61.3.2201335.18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD) \u2013 a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"2024102103094943000_61.3.2201335.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.09.005"},{"key":"2024102103094943000_61.3.2201335.20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s00106-007-1606-9","article-title":"Entwicklung einer Bewertungsskala f\u00fcr den Sino-Nasal Outcome Test-20 German Adapted Version (SNOT-20 GAV) [Development of a grading scale for the Sino-Nasal Outcome Test-20 German Adapted Version (SNOT-20 GAV)]","volume":"56","author":"Baumann","year":"2008","journal-title":"HNO"},{"key":"2024102103094943000_61.3.2201335.21","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-198402000-00004"},{"key":"2024102103094943000_61.3.2201335.22","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103094943000_61.3.2201335.23","doi-asserted-by":"crossref","first-page":"e27471","DOI":"10.1097\/MD.0000000000027471","article-title":"Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab","volume":"100","author":"Bertlich","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2024102103094943000_61.3.2201335.24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/all.15134","article-title":"Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"77","author":"Lans","year":"2022","journal-title":"Allergy"},{"key":"2024102103094943000_61.3.2201335.25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102103094943000_61.3.2201335.26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103094943000_61.3.2201335.27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaip.2021.09.037","article-title":"Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102103094943000_61.3.2201335.28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/lio2.485","article-title":"Olfaction: sensitive indicator of inflammatory burden in chronic rhinosinusitis","volume":"5","author":"Yan","year":"2020","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"2024102103094943000_61.3.2201335.29","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2020.11.001","article-title":"Inflammatory heterogeneity in aspirin-exacerbated respiratory disease","volume":"147","author":"Scott","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103094943000_61.3.2201335.30","doi-asserted-by":"publisher","DOI":"10.1111\/all.13559"},{"key":"2024102103094943000_61.3.2201335.31","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13401"},{"key":"2024102103094943000_61.3.2201335.32","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102103094943000_61.3.2201335.33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.1.123"},{"key":"2024102103094943000_61.3.2201335.34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102103094943000_61.3.2201335.35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jaci.2019.08.022","article-title":"Aspirin sensitivity: lessons in the regulation (and dysregulation) of mast cell function","volume":"144","author":"Boyce","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024102103094943000_61.3.2201335.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70167-7"},{"key":"2024102103094943000_61.3.2201335.37","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"2024102103094943000_61.3.2201335.38","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1945892420972326","article-title":"Effects of omalizumab treatment in patients with recalcitrant nasal polyposis and mild asthma: a multicenter retrospective study","volume":"35","author":"Armengot-Carceller","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"2024102103094943000_61.3.2201335.39","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01335-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:12:19Z","timestamp":1740359539000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01335-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,16]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1183\/13993003.01335-2022"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01335-2022","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}